Ascendis Pharma A/S (ASND) is under pressure as investors react to the company’s decision to redeem all $575.0 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2028. Corporate actions involving convertible securities can drive short-term stock volatility as holders and arbitrage desks adjust exposures (including delta-hedges) and reassess whether to convert into shares or take cash at redemption. (investors.ascendispharma.com)

Ascendis set the redemption date for May 6, 2026, and disclosed that each $1,000 principal amount of notes is redeemable for about $1,002.19, with the notes also convertible into 6.0118 shares per $1,000 principal amount (implying a conversion price near $166.34 per share). With ASND trading well above that implied conversion price, the market is weighing how much conversion activity could effectively increase share count and how quickly any associated hedges get unwound. (stocktitan.net)

The move comes during an active corporate/operational stretch for Ascendis, including changes to how its shares trade on Nasdaq (direct listing mechanics and ADS exchange) that can add friction for some investors and incremental volatility around positioning. Against that backdrop, a large convert redemption can become the dominant near-term driver even if the company’s longer-term narrative remains centered on commercialization execution and pipeline milestones. (investing.com)